• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by I-MAB

    9/11/25 4:36:16 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    S-8 1 imab-20250911.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on September 11, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    I-Mab

    (Exact name of registrant as specified in its charter)

    Cayman Islands

    (State or other jurisdiction of

    incorporation or organization)

    Not Applicable

    (I.R.S. Employer

    Identification No.)

     

     

    I-Mab

    2440 Research Boulevard, Suite 400

    Rockville, MD

    (Address of principal executive offices)

    20850

    (Zip Code)

    I-Mab 2025 Omnibus Share Incentive Plan

    AND

    2025 Share Incentive Scheme

    (Full titles of the plan)

    Joseph Skelton
    Chief Financial Officer
    2440 Research Boulevard, Suite 400
    Rockville, MD 20850
    (Name and address of agent for service)

    (240) 745-6330
    (Telephone number, including area code, of agent for service)

    Copies to:

    Christian Plaza

    Mark Ballantyne

    Paul Alexander

    Cooley LLP

    11951 Freedom Drive

    Reston, VA 20190-5640

    (703) 456-8000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ¨

    Accelerated filer

    ¨

    Non-accelerated filer x

    Smaller reporting company

    ¨

    Emerging growth company

    ¨

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

    The Registration Statement shall become effective upon filing in accordance with Rule 462 under the Securities Act.

     

     

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information*

    Item 2. Registrant Information and Employee Plan Annual Information*

    *Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this registration statement on Form S-8 (this “Registration Statement”) in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the “Note” to Part I of Form S-8. The documents containing the information specified in this Part I of Form S-8 will be separately provided to the participants in the Registrant’s 2025 Omnibus Share Incentive Plan and 2025 Share Incentive Scheme covered by this Registration Statement, as specified by the U.S. Securities and Exchange Commission (the “SEC” or the “Commission”) pursuant to Rule 428(b)(1) under the Securities Act. Such documents are not required to be, and are not, filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents have been filed by the Registrant with the Commission and are incorporated herein by reference:

    •
    the Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 filed with the SEC on April 3, 2025, which Annual Report contains the audited financial statements for the Registrant’s last fiscal year (File No. 001-39173);
    •
    the Registrant’s Current Reports on Form 6-K filed with the SEC on January 6, 2025, January 29, 2025, March 7, 2025, March 21, 2025 and April 3, 2025; May 15, 2025, May 30, 2025, July 11, 2025 (Film No. 251119039), July 11, 2025 (Film No. 251119296), July 17, 2025; August 1, 2025; August 4, 2025; August 11, 2025; August 20, 2025; August 25, 2025; and September 8, 2025 (File No. 001-39173); and
    •
    the description of the Registrant’s securities, contained in the Registrant’s registration statement on Form 8-A (File No. 001-39173) filed with the Commission on January 3, 2020, including any amendment and report subsequently filed for the purpose of updating such description.

     

    In addition, all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (excluding any portions thereof furnished by the Registrant, including but not limited to any certification required by 18 U.S.C. § 1350), on or after the date of this Registration Statement, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     


     

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Cayman Islands law does not limit the extent to which a company’s articles of association may provide for indemnification of directors and officers, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. The Registrant’s Sixth Amended and Restated Memorandum and Articles of Association, adopted by its shareholders on October 29, 2019, provides that the Registrant shall indemnify each of its directors and officers against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such director or officer, other than by reason of such person’s own dishonesty, willful default or fraud, in or about the conduct of the Registrant’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning the Registrant or its affairs in any court whether in the Cayman Islands or elsewhere.

    Pursuant to the indemnification agreements, the form of which was filed as Exhibit 10.3 to the Registrant’s registration statement on Form F-1, as amended (File No. 333-234363), the Registrant has agreed to indemnify its directors and officers to the fullest extent permitted by law against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

    The Registrant also maintains a directors and officers liability insurance policy for its directors and officers.

    Item 7. Exemption from Registration Claimed.

    Not Applicable.

     

     

     


     

    Item 8. Exhibits.

    Exhibit Number

    Description

    4.1

    Sixth Amended and Restated Memorandum and Articles of Association of I-Mab (incorporated herein by reference to Exhibit 3.2 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed on October 29, 2019).

    4.2

    Specimen Certificate for Ordinary Shares of I-Mab (incorporated herein by reference to Exhibit 4.2 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed on October 29, 2019).

    4.3

    Deposit Agreement, dated as of January 22, 2020, among I-Mab, the depositary and holder of the American Depositary Receipt (incorporated herein by reference to Exhibit 4.3 to the registration statement on Form S-8 (File No. 333-239871), as amended, initially filed with the SEC on July 15, 2020).

    5.1*

    Opinion of Harney Westwood & Riegels, Cayman Islands counsel to I-Mab, regarding the legality of the Ordinary Shares being registered.

     

     

     

    10.1*+

     

    I-Mab 2025 Omnibus Share Incentive Plan and the Forms of Option Agreement and Restricted Share Unit Agreement thereunder.

     

     

     

    10.2*+

    I-Mab 2025 Share Incentive Scheme (including proxy form, notice of grant, notice of exercise and share purchase agreement and investment representation statement).

    23.1*

    Consent of PricewaterhouseCoopers LLP, an independent registered public accounting firm.

     

     

     

    23.2*

    Consent of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm.

    23.3*

    Consent of Harney Westwood & Riegels (included in Exhibit 5.1).

    24.1*

    Power of Attorney (included on the signature page hereto).

    107*

    Filing Fee Table.

     

    * Filed herewith.

    + Indicates management contract or compensatory plan or arrangement

     

     

     

     

     

     

    Item 9. Undertakings.

     

     

     

     


     

    1.

    The undersigned registrant hereby undertakes:

    (a)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)

    To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective Registration Statement; and

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference herein.

    (b)

    That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2.

    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933 each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3.

    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     

    SIGNATURES

     

     

     


     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Rockville, State of Maryland, on the 11th day of September, 2025.

     

    I-Mab

     

    /s/ Joseph Skelton

    Name: Joseph Skelton

    Title: Chief Financial Officer

     

     

     


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Joseph Skelton and Sean Fu, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8 and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each of said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-facts and agents, or his or her substitutes or resubstitutes, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

     

     

    /s/ Sean Fu, PhD, MBA

    Chief Executive Officer and Director

    September 11, 2025

    Sean Fu, PhD, MBA

    (Principal Executive Officer)

     

     

    /s/ Joseph Skelton

    Chief Financial Officer

    September 11, 2025

    Joseph Skelton

    (Principal Financial and Accounting Officer)

     

     

    /s/ Wei Fu

    Executive Chairman

    September 11, 2025

    Wei Fu

    /s/ Sean Cao, PhD

    Chief Business Development Officer and Director

    September 11, 2025

    Sean Cao, PhD

    /s/ Dr. Robert Lenz

    Director

    September 11, 2025

    Dr. Robert Lenz

    /s/ Xin Liu

    Director

    September 11, 2025

    Xin Liu

    /s/ Chun Kwok Alan Au

    Director

    September 11, 2025

    Chun Kwok Alan Au

    /s/ Conor Chia-hung Yang

    Director

    September 11, 2025

    Conor Chia-hung Yang

     

     

     

     


     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of I-Mab, has signed this Registration Statement on Form S-8 in Rockville, Maryland on September 11, 2025.

    I-Mab Biopharma US Ltd.

    Authorized U.S. Representative

    /s/ Joseph Skelton

    Name: Joseph Skelton

    Title: Chief Financial Officer

    8

     


    Get the next $IMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    9/9/2025$7.00Buy
    BTIG Research
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    SEC Filings

    View All

    SEC Form S-8 filed by I-MAB

    S-8 - I-Mab (0001778016) (Filer)

    9/11/25 4:36:16 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    9/8/25 8:10:53 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/25/25 7:09:48 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

    Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC)Mr. Wei Fu, I-Mab's Chairman of the Board of Directors, appointed as Executive Chairman, supported by further executive additions ROCKVILLE, Md., Sept. 08, 2025 (GLOBE N

    9/8/25 8:30:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

    Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of

    8/25/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab to Participate in September Investor Conferences

    ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the following upcoming investor conferences in September, 2025: Conference details are as follows: Cantor Global Healthcare ConferenceFormat: One-on-one meetingsDate: September 3-5, 2025 H.C. Wainwright 27th Annual Global Investment ConferenceFormat: Company presentation and one-on-one meetingsDate: Wednesday, September 10, 2025Time: 9:30 AM ETWebcast Link: Here The webcast of the company pres

    8/21/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on I-Mab with a new price target

    BTIG Research initiated coverage of I-Mab with a rating of Buy and set a new price target of $7.00

    9/9/25 7:57:49 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Siebert Williams Shank initiated coverage on I-Mab with a new price target

    Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

    12/9/21 8:33:47 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on I-MAB with a new price target

    Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

    11/1/21 4:39:06 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

    Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC)Mr. Wei Fu, I-Mab's Chairman of the Board of Directors, appointed as Executive Chairman, supported by further executive additions ROCKVILLE, Md., Sept. 08, 2025 (GLOBE N

    9/8/25 8:30:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

    Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of

    8/25/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

    Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

    4/3/25 4:01:00 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Financials

    Live finance-specific insights

    View All

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

    10/31/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

    Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

    8/28/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

    8/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/13/24 11:26:50 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/9/24 4:01:20 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by I-MAB

    SC 13D - I-Mab (0001778016) (Subject)

    12/1/23 2:41:06 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care